Last: | $142.98 |
---|---|
Change Percent: | 2.56% |
Open: | $141.69 |
Close: | $142.98 |
High: | $143.37 |
Low: | $139.03 |
Volume: | 5,900,099 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$142.98 | $141.69 | $142.98 | $143.37 | $139.03 | 5,900,099 | 07-02-2024 |
$145.42 | $143.59 | $145.42 | $145.99 | $143.56 | 3,435,776 | 07-01-2024 |
$142.74 | $144.66 | $142.74 | $145.59 | $142.67 | 2,757,544 | 06-28-2024 |
$144.49 | $143.86 | $144.49 | $145.36 | $143.43 | 2,592,441 | 06-27-2024 |
$143.67 | $145.56 | $143.67 | $145.6193 | $142.7941 | 4,384,515 | 06-26-2024 |
$146.91 | $145.51 | $146.91 | $148.15 | $144.68 | 6,341,691 | 06-25-2024 |
$142.28 | $141.87 | $142.28 | $142.66 | $141.51 | 2,992,090 | 06-24-2024 |
$141.96 | $141.46 | $141.96 | $142.56 | $141.21 | 3,033,303 | 06-21-2024 |
$140.99 | $141.51 | $140.99 | $143.59 | $140.81 | 3,205,591 | 06-20-2024 |
$140.8 | $141.06 | $140.8 | $141.71 | $139.78 | 2,640,226 | 06-19-2024 |
$140.8 | $141.06 | $140.8 | $141.71 | $139.78 | 2,640,226 | 06-18-2024 |
$140.37 | $142 | $140.37 | $142.13 | $140.34 | 3,164,448 | 06-17-2024 |
$142.5 | $142.21 | $142.5 | $143.18 | $141.89 | 2,831,653 | 06-14-2024 |
$142.49 | $142.83 | $142.49 | $142.91 | $141.14 | 2,857,184 | 06-13-2024 |
$143.26 | $143.52 | $143.26 | $144.5 | $142 | 3,242,786 | 06-12-2024 |
$141.79 | $141.91 | $141.79 | $142.94 | $141.02 | 4,433,332 | 06-11-2024 |
$143.63 | $142.115 | $143.63 | $143.94 | $141.25 | 3,655,019 | 06-10-2024 |
$142.88 | $143.07 | $142.88 | $143.73 | $142.27 | 3,511,197 | 06-07-2024 |
$142.4 | $141.19 | $142.4 | $142.94 | $140.8901 | 4,369,174 | 06-06-2024 |
$141 | $141.36 | $141 | $142.4095 | $140.08 | 3,786,730 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
2024-07-02 11:54:16 ET Shares of Novo Nordisk (NYSE: NVO) were slipping 1.7% lower as of 10:57 a.m. ET on Tuesday, after falling as much as 4.4% earlier in the day. The decline came after USA Today published an opinion piece in which President Joe Biden and independent Senator B...
2024-06-30 09:15:00 ET Novo Nordisk (NYSE: NVO) has emerged as one of the biggest names in the pharmaceutical world thanks to its robust line of glucagon-like peptide-1 (GLP-1) medicines. The Danish drugmaker develops Ozempic, Rybelsus, Saxenda, and Wegovy. While Ozempic is appr...
2024-06-29 11:34:00 ET For most of its existence, Altimmune (NASDAQ: ALT) has been a little-known biotech aspiring to compete in a world dominated by whales like Novo Nordisk (NYSE: NVO) , the maker of the hit weight loss drug Wegovy and the blockbuster Ozempic for type 2 di...